185: Feasibility of autologous stem cell transplant followed by reduced intensity allogeneic stem cell transplantation for high risk neuroblastoma

Yamashiro, Darrell J.; Lee, A.; Bhatia, Monica; Bender, Julia Glade; Qualter, E.; Militano, Olga; Harrison, Lauren; Davenport, Virginia; Cheung, Ken; Bradley, M.B.; Garvin, James H.; Toro, G. Del; Cairo, Mitchell S.

doi:10.1016/j.bbmt.2006.12.189

Cited by 8 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For neuroblastoma patients, in case of detectable tumor cells in the product by immunocytology, CD34 cells were selected using the Isolex 300i system (Baxter Immunotherapy, Round Lake, IL, USA) or the CliniMacs system (Miltenyi Biotec, Auburn, CA, USA). 15 …”

Section: Patientsmentioning

confidence: 99%

Pericardial effusion post-SCT in pediatric recipients with signs and/or symptoms of cardiac disease

Neier

Jin

Kleinman

et al. 2010

Bone Marrow Transplant

View full text Add to dashboard Cite

The objective of this study was to assess the incidence, risk factors, outcome and impact on OS of pericardial effusion (PEF) in a cohort of 156 pediatric SCT recipients. The mean age was 8.15 ± 6.25 years. In all, 74% of the patients had malignant disease and 35% of the patients received autologous stem cell grafts. Twenty-three subjects developed effusion at 2.75 ± 3.54 months after SCT. The overall probability of developing a PEF after SCT was 16.9%. In the multivariate analysis of risk factors associated with time to PEF, increased age, allogeneic risk status and conditioning type, were all significant factors. In a multivariate analysis of time to death, PEF, CMV status and risk status were all independent risk factors. PEF, however, had the highest HR of 3.334. Of the 23 patients with PEF, 19 died (82.6%); however, none died as a direct result of pericardial tamponade. In summary, our results suggest that PEF is a significant risk factor for post transplant mortality. These results suggest a need for more frequent evaluation and monitoring for development of PEF. Studies are needed to determine the etiology of, and new therapeutic strategies for, PEF in the post-SCT population.

show abstract

Section: Patientsmentioning

confidence: 99%

Pericardial effusion post-SCT in pediatric recipients with signs and/or symptoms of cardiac disease

Neier

Jin

Kleinman

et al. 2010

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…All five patients were alive, with no evidence of disease, with median time from diagnosis of 41 m (26-50 m). 18 In France, four patients were recently treated according to a protocol on the basis of fludarabine, BU and antilymphocyte serum (ALS) RIC. All received high-dose chemotherapy with auto-HSCT as first-line treatment.…”

Section: Ric Allo-hsctmentioning

confidence: 99%

Allogeneic or haploidentical HSCT for refractory or relapsed solid tumors in children: toward a neuroblastoma model

Kanold

Paillard

Tchirkov

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

New concepts of allogeneic hematopoietic SCT (allo-HSCT) for neuroblastoma and other solid tumors do not rely on escalation of chemotherapy intensity and tumor load reduction but rather on a graft-vs-tumor effect. At this point, this is still an investigational and unusual application of allogeneic transplant, with 78 neuroblastoma patients reported to the European Group for Blood and Marrow Transplantation activity survey from 2002 to 2007 and less than 100 published cases. Two trends can be observed in the reviewed data: some teams have used allo-HSCT in children with refractory or progressive disease and significant tumor burden and other teams in children with CR, PR or minimal residual disease earlier in their disease process. Early studies of allo-HSCT in children with high-risk neuroblastoma suggest that this is a feasible approach that may improve outcome in this deadly disease. However, the proper timing for allo-HSCT during the disease course remains to be determined.

show abstract

“…RI-UCBT should be considered for pediatric patients whose condition at the time of transplantation places them at a high risk of toxicity (co-morbidities) from myeloablative transplantation. Studies are ongoing to determine the place of RI-UCBT in standard-risk pediatric hematological malignancies, 62 pediatric solid tumors 63 and selected non-malignant diseases. 34 The optimal intensity of conditioning for individual diseases, particularly CML, HLH and b-thalassemia, remains to be elucidated.…”

Section: Survivalmentioning

confidence: 99%

Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases

Bradley

Satwani

Baldinger

et al. 2007

Bone Marrow Transplant

View full text Add to dashboard Cite

185: Feasibility of autologous stem cell transplant followed by reduced intensity allogeneic stem cell transplantation for high risk neuroblastoma

Cited by 8 publications

References 0 publications

Pericardial effusion post-SCT in pediatric recipients with signs and/or symptoms of cardiac disease

Pericardial effusion post-SCT in pediatric recipients with signs and/or symptoms of cardiac disease

Allogeneic or haploidentical HSCT for refractory or relapsed solid tumors in children: toward a neuroblastoma model

Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases

Contact Info

Product

Resources

About